The Israel Defense Forces on Sunday hit targets in southern Lebanon with artillery, after Hezbollah terrorists there fired mortars at the Jewish state.

There were no reports of casualties or damage.

The shells landed in the contested Mount Dov region close to the Blue Line, which demarcates the 120-kilometer (75 mile) border and was created in 2000 by U.N. cartographers to verify Israel’s withdrawal from Lebanon.

“We targeted three Israeli military sites in solidarity with the “Palestinian resistance,” said Hezbollah as it claimed responsibility for Sunday’s fire.

In response, the IDF carried out a drone strike against “Hezbollah infrastructure,” with Israeli media reporting the targeting of a tent the Iran-backed terror group set up in Israeli territory in April.

The Hezbollah outpost was constructed north of the border fence but on the Israeli side of the U.N.-marked Blue Line. The position, located across from an Israeli military base, was reportedly initially manned by three to eight armed terrorists.

Hezbollah does not recognize the Blue Line and disputes numerous points along the border.

Last month, the IDF bolstered its forces on the country’s northern border after a Lebanese “engineering vehicle” strayed a few meters into Israeli territory. In July, the IDF revealed that armed Hezbollah terrorists were spotted patrolling the border in clear violation of a legally binding U.N. resolution.

On March 15, a terrorist who infiltrated into Israel from Lebanon planted a roadside bomb in northern Israel that severely wounded a motorist. Shareef ad-Din, 21, from the Israeli Arab town of Salem, was caught in the blast when the device detonated behind a road barrier near the Megiddo Junction, some 18 miles southeast of Haifa.

“Saturday’s Devastating multi-pronged Hamas attack on Israel was in response to both the “continued occupation and a message to those seeking normalization with it,” said Hezbollah.

The United States has been working on a landmark peace deal between Israel and Saudi Arabia, which many believed could be signed in the coming months.

Hamas killed more than 250 Israelis on Saturday—the Jewish holiday of Simchat Torah—as it launched a massive offensive from the Gaza Strip, including firing more than 3,000 rockets and sending dozens of Palestinian terrorists to infiltrate the Jewish state.

In April, Hamas fired 34 rockets from southern Lebanon towards northern Israel in the biggest attack emanating from the Hezbollah-controlled country since the 2006 war.

Produced in association with Jewish News Syndicate

Edited by Judy J. Rotich and Newsdesk Manager

Israel’s Security Cabinet early on Sunday morning made a series of decisions marking the start of the offensive phase of “Operation Swords of Iron,” ordering the Israel Defense Forces to prepare for the “destruction of the military and governing capabilities of Hamas and [Palestinian] Islamic Jihad.”

“We are embarking on a long and difficult war that was forced on us by a murderous Hamas attack,” said Israeli Prime Minister Netanyahu.

“We will restore security to the citizens of Israel and we will win,” he vowed.

“The first stage is ending at this time with the destruction of the vast majority of the enemy forces that infiltrated our territory. At the same time, we have begun the offensive phase, which will continue with neither limitations nor respite until the objectives are achieved,” he added.

Among the Cabinet’s decisions was to halt the supply of electricity, fuel and goods to the Gaza Strip.

As Israel readied its response to Saturday’s attacks, four divisions of reservists were being deployed to the Gaza border, joining the 35 battalions already deployed to the area, the army said.

Hamas killed at least 250 Israelis and wounded more than 1,800 on Saturday in a massive offensive launched from the Gaza Strip, including firing thousands of rockets and sending dozens of terrorists to infiltrate the Jewish state.

Of the 1,864 wounded, 19 remain in critical condition, the Israeli Health Ministry announced on Sunday morning. In addition, 326 Israelis sustained severe wounds, while 359 were moderately wounded.

”821 people suffered light injuries, 20 were treated for anxiety and another 223 are under medical supervision,” said the Health Ministry’s most recent figures.

Hamas claims to have taken 163 Israeli captives to Gaza. Channel 13 reported late Saturday afternoon that Israel has confirmed that at least 11 people have been taken hostage in the Hamas-ruled enclave.

Overnight Saturday, Palestinian terrorist groups in the Gaza Strip continued to fire rockets at Israel’s southern region, with a direct hit reported at Ashkelon’s Barzilai Medical Center. The projectile struck a bridge between hospital buildings and no casualties were reported, Channel 12 said.

Meanwhile, security forces, including 35 IDF battalions, continued their search for Hamas infiltrators throughout southern communities. Following a day-long standoff, hostages were freed after exchanges of fire in Kibbutz Be’eri and Ofakim.

Control was also regained over the area surrounding the police station in Sderot, where 10 Hamas terrorists were killed after the Israel Police ordered the building destroyed.

Produced in association with Jewish News Syndicate

Edited by Judy J. Rotich and Newsdesk Manager

A week filled with significant events impacting the markets culminated in an unexpectedly strong September jobs report.

The U.S. Congress managed to avoid a dramatic government shutdown just hours before the midnight deadline Oct. 1 by passing a stopgap funding bill. This bill ensures the continuation of government operations through Nov. 17, excluding new funding for border security and Ukraine. On Tuesday, the House of Representatives made a historic decision to oust Speaker Kevin McCarthy, following a motion initiated by Rep. Matt Gaetz (R-FL) in response to McCarthy’s collaboration with Democrats to prevent a government shutdown.

Throughout the week, yields across the Treasury curve continued to rise. The 10-year Treasury yield surged past 4.75%, reaching its highest level in 16 years. On Friday, the 30-year yield crossed the 5% threshold, driven by a jobs report that exceeded expectations. Funds and ETFs investing in long-dated Treasury bonds such as the PIMCO 25 Year Zero Coupon U.S. Treasury Index Exchange-Traded Fund (NYSE:ZROZ) or the iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT) have now lost more than 50% of their value since March 2020.

 The September jobs report showed stronger-than-anticipated employment growth. Non-farm payrolls increased by 337,000 last month, marking the largest monthly gain since January and far surpassing the expected 170,000. August NFPs were revised upward to 227,000, indicating a robust pace of hiring throughout late summer. As a result of the impressive jobs number, economists now see rising risks of further Federal Reserve tightening this quarter.

On the consumer front, Walmart reported a decrease in shopping demand attributed to the use of weight-loss and appetite-suppressing drugs such as Ozempic and Wegovy, manufactured by Novo Nordisk A/S (NYSE:NVO). Shares of beverage giants like The Coca-Cola Company (NYSE:KO) and PepsiCo Inc. (NYSE:PEP) had their worst-performing week since May 2022.

Oil giant Exxon Mobil Corp. (NYSE XOM) is considering acquiring Pioneer Natural Resources Company (NYSE:PXD) to strengthen its position in the U.S. energy sector. The potential agreement could be valued at up to $60 billion, potentially making it the largest takeover in the world this year. Shares of the target company, Pioneer, rose by as much as 10% on Friday.

 The S&P 500, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), rebounded from four consecutive weeks of declines. Similarly, the Nasdaq 100, monitored via the Invesco QQQ Trust (NASDAQ:QQQ), posted weekly gains and recorded its strongest session since late August on Friday.

Notable sectors that displayed strength this week included the Technology Select Sector SPDR Fund (NYSE:XLK), which rose by 3%, the Communication Services Select Sector SPDR Fund (NYSE:XLC), gaining 2.1%, and the Health Care Select Sector SPDR Fund (NYSE:XLV), which registered a 1.1% increase.

Among the mega-cap stocks in the S&P 100, top performers for the week included Alphabet Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL), Nvidia Corp. (NASDAQ:NVDA), Eli Lilly & Company (NYSE:LLY), and Meta Platforms Inc. (NASDAQ:META), all of which posted gains exceeding 5%. NextEra Energy Inc. (NYSE:NEE) was the laggard, down over 12% for the week.

All eyes are on the Consumer Price Index report for September set to be released on Thursday. This report will mark the last crucial piece of economic data ahead of the Nov. 1 Fed meeting. Economists predict that the annual inflation rate will slightly ease from 3.7% to 3.6% in September, and core inflation is expected to fall from 4.3% to 4.1% on a year-over-year basis. 

Other relevant economic releases include the Producer Price Index report on Wednesday, where a monthly decline from 0.7% to 0.3% is expected, and the Michigan Consumer Sentiment estimate for October on Friday.

On the earnings front, PepsiCo will report on Tuesday, while Thursday will feature Infosys Limited (NYSE:INFY), Fastenal (NASDAQ:FAST), Delta Air Lines (NYSE:DAL), Walgreens Boots Alliance (NASDAQ:WBA), and Domino’s Pizza (NYSE:DPZ). Some major financial institutions will report Friday, include JPMorgan Chase & Co. (NYSE:JPM), BlackRock (NYSE:BLK), Citigroup (NYSE:C), Wells Fargo (NYSE:WFC), PNC Financial Services (NYSE:PNC), along with UnitedHealth Group (NYSE:UNH), and The Progressive Corp (NYSE:PGR).

Produced in association with Benzinga

“Long colds” are a thing – just like long COVID, suggests a new study.

People may experience long-term symptoms for several weeks or more – or ‘long colds’ – after acute respiratory infections that test negative for COVID-19, say scientists.

Some of the most common symptoms of the ‘long cold’ included coughing, stomach pain, and diarrhea more than four weeks after initial infection, according to the research team from Queen Mary University of London.

While the severity of an illness appears to be a key driver of the risk of long-term symptoms, they say more research is being conducted to establish why some people suffer extended symptoms while others don’t.

The findings, published in The Lancet’s EClinicalMedicine, suggest that there may be long-lasting health impacts following non-COVID acute respiratory infections such as colds, flu, or pneumonia, that are currently going unrecognized.

However, the researchers do not yet have evidence suggesting that the symptoms have the same severity or duration as long COVID.

Study lead author Giulia Vivaldi said: “Our findings shine a light not only on the impact of long COVID on people’s lives but also other respiratory infections.

“A lack of awareness – or even the lack of a common term – prevents both reporting and diagnosis of these conditions.

“As research into long COVID continues, we need to take the opportunity to investigate and consider the lasting effects of other acute respiratory infections.

“These ‘long’ infections are so difficult to diagnose and treat primarily because of a lack of diagnostic tests and there being so many possible symptoms.

“There have been more than 200 investigated for long COVID alone.”

The research compared the prevalence and severity of long-term symptoms after a bout of COVID-19 with a bout of another acute respiratory infection that tested negative for COVID.

Those recovering from COVID-19 were more likely to experience light-headedness or dizziness plus problems with taste and smell compared to those who had a non-COVID respiratory infection.

While long COVID is now a recognized condition, there have been few studies comparing long-term symptoms following SARS-CoV-2 coronavirus infection with other respiratory infections.

The study is the latest output from COVIDENCE UK, Queen Mary University of London’s national study of COVID-19, launched in 2020 and still in follow-up, with more than 19,000 participants enrolled.

The latest research analyzed data from more than 10,000 UK adults, with responses collected via questionnaires and statistical analysis conducted to identify symptom clusters.

Professor Adrian Martineau, Chief Investigator of COVIDENCE UK, said: “Our findings may chime with the experience of people who have struggled with prolonged symptoms after having a respiratory infection despite testing negative for COVID-19 on a nose or throat swab.”

He added: “Ongoing research into the long-term effects of COVID-19 and other acute respiratory infections is important because it can help us to get to the root of why some people experience more prolonged symptoms than others.

“Ultimately this could help us to identify the most appropriate form of treatment and care for affected people.”

Victoria King, of Barts Charity which funded the research, said: “These findings highlight not only the long-term symptoms experienced by people after COVID infection, but by people after other acute respiratory infections as well.

“As we learn more about long COVID symptoms and their possible treatments, studies like this help to build greater awareness around other prolonged respiratory infections that may be going unrecognised.”

Produced in association with SWNS Talker

A world-first research breakthrough has sparked fresh hope for patients with the same cancer that killed Dame Deborah James.

Australian scientists have discovered a new “roadmap” to beating bowel cancer.

They found an important group of immune cells in the large bowel – called gamma delta T cells – are “crucial” to prevent the disease that claims tens of thousands of lives every year.

The breakthrough was made by researchers at the Olivia Newton-John Cancer Research Institute in Heidelberg, Australia, named after the Anglo-Aussie singer who succumbed to cancer, aged 73, last year.

The BBC journalist and podcast presenter chronicled her battle with early onset bowel cancer, before her death, aged 40, in June last year.

The research team says there is an “urgent” need to discover more effective treatments and improve bowel cancer screening, particularly for early-onset bowel cancer as Australians born in 1990 onwards have double the risk of developing bowel cancer compared with those born in 1950.

They said younger bowel cancer patients often have poorer outcomes as they only turn to their doctor when the disease is already in its later stages.

Immunotherapy is one of the most promising new treatments for cancer. It involves boosting the ability of immune cells to recognize and remove cancer cells.

However, less than one-in-10 bowel cancer patients respond to current immunotherapies.

Study principal investigator Dr. Lisa Mielke said: “We have discovered that an important group of immune cells in the large bowel – gamma delta T cells – are crucial to preventing bowel cancer.

“Gamma delta T cells act as our frontline defenders in the bowel.

“What makes these immune cells extraordinary is that they constantly patrol and safeguard the epithelial cells lining the bowel, acting as warriors against potential cancer threats.

“When we analyzed bowel cancer patient samples, we found that when more gamma delta T cells were present in the tumors, these patients were reported to have better outcomes and improved survival.”

She explained that the large bowel contains trillions of bacteria, viruses and fungi, collectively known as the microbiome.

While some bacteria are associated with disease, others are extremely important for the immune system.

Study co-lead author Marina Yakou says the research may lead to improved treatments for cancer patients in the future.

She said: “We discovered that the amount, and diversity of, the microbiome in the large bowel resulted in a higher concentration of a molecule called TCF-1 on Gamma delta T cells compared to other areas of the gut.

“This molecule (TCF-1) suppresses our natural immune response, the gamma delta T cells, from fighting off bowel cancer.

“When we deleted TCF-1 in gamma delta T cells using pre-clinical models, this fundamentally changed the behavior of these immune cells and we saw a remarkable reduction in the size of bowel cancer tumors.”

Yakou, a PhD candidate at the Olivia Newton-John Cancer Research Institute, added: “Our world-first research breakthrough paves a new roadmap for developing targeted combination immunotherapies to more effectively treat bowel cancer patients.”

The researchers say their findings, published in the journal Science Immunology, also open up new possibilities for understanding how the microbiome and immune cells in the bowel interact – which could lead to the development of new ways to lower the risk of bowel cancer and better screening.

The breakthrough was welcomed by 36-year-old bowel cancer patient, Elise Stapleton, who was initially diagnosed with reoccurring endometriosis.

But, in January this year, she received a shock diagnosis of Stage 3 bowel cancer.

She said: “After waking up from my surgery to remove endometriosis, the bombshell hit.

“Instead of a planned keyhole surgery, surgeons told me that they had found a tumor and performed open surgery to remove ‘what they could’.

“I then had a second operation to remove 20 to 25 centimeters (0.82 foot) of my large bowel, follow up chemotherapy in April; and I have side-effects from the surgery and treatment.”

Elise continued: “My life has changed dramatically. After having been through a lot in a very short amount of time this year, I’m now feeling very empowered.

“I want to help raise awareness with young people that bowel cancer is not just an older person’s disease and to trust your instincts – if something doesn’t seem right, then keep following it up with health professionals.”

She added: “I’m hopeful that this new research may lead to more targeted immunotherapies that will result in less side effects, and hopefully even one day help to design better screening so people can be more accurately diagnosed and treated earlier.”

Produced in association with SWNS Talker

Running is as good for beating depression as medication and leaves you fitter, according to the first study of its kind.

Researchers from Vrije University, Amsterdam, found 44 percent of people with depression and anxiety started to feel better if they spent 16 weeks going on runs, or 16 weeks taking antidepressants.

Participants either joined a supervised running group two or three times a week or took SSRI escitalopram as prescribed.

The majority picked exercise, and their treatment also improved their weight, waist circumference, blood pressure and heart function.

Meanwhile, people who took antidepressants tended to become less fit.

However, experts insisted that telling patients to go run is not enough, noting that a larger portion of the runners dropped out, with just 52 percent sticking to the plan versus 82 percent of those taking the pills.

Speaking at the European College of Neuropsychopharmacology conference in Barcelona, Professor Brenda Penninx said: “We wanted to compare how exercise or antidepressants affect your general health, not just your mental health.

“This study gave anxious and depressed people a real-life choice, medication or exercise.

“Interestingly, the majority opted for exercise, which led to the numbers in the running group being larger than in the medication group.

“Both interventions helped with the depression to around the same extent. Antidepressants generally had worse impact on body weight, heart rate variability and blood pressure, whereas running therapy led to improved effect on general fitness and heart rate for instance.

“We are currently looking in more detail for effects on biological aging and processes of inflammation.

“It is important to say that there is room for both therapies in care for depression.

“The study shows that lots of people like the idea of exercising, but it can be difficult to carry this through, even though the benefits are significant.

“We found that most people are compliant in taking antidepressants, whereas around half of the running group adhered to the two-times-a-week exercise therapy.

“Telling patients to go run is not enough. Changing physical activity behavior will require adequate supervision and encouragement as we did by implementing exercise therapy in a mental health care institution.”

Her team offered 141 depression and or anxiety patients a choice of SSRI antidepressants for 16 weeks or running in a group two or three times a week for the same period of time.

Overall, 45 selected medications and 96 running.

Those who chose medication were slightly more depressed than the runners.

The antidepressant group had to take SSRI escitalopram as prescribed for 16 weeks, but that did not generally impact on their daily behaviors.

Meanwhile, runners aimed for two to three closely supervised 45-minute group sessions a week for 16 weeks.

The exercise tackled. the sedentary lifestyle that often accompanies depression and anxiety, encouraging people to head outside, set goals, improve fitness and get involved in a group activity.

Professor Penninx added: “Antidepressants are generally safe and effective. They work for most people.

“We know that not treating depression at all leads to worse outcomes; so antidepressants are generally a good choice.

“Nevertheless, we need to extend our treatment arsenal as not all patients respond to antidepressants or are willing to take them.

“Our results suggest that implementing exercise therapy is something we should take much more seriously, as it could be a good – and maybe even better – choice for some of our patients.

“In addition, let’s also face potential side effects our treatments can have.

“Doctors should be aware of the dysregulation in nervous system activity that certain antidepressants can cause, especially in patients who already have heart problems.

“This also provides an argument to seriously consider tapering and discontinuing antidepressants when depressed or anxious episodes have remitted.

“In the end, patients are only truly helped when we are improving their mental health without unnecessarily worsening their physical health”.

Dr. Eric Ruhe, Amsterdam University Medical Centres, said the impact of the findings could be huge.

Commenting on the study originally published in the Journal of Affective Disorders, he said: “These are very interesting results that again show that physical health can influence mental health and that treatment of depression and anxiety can be achieved by exercising, obviously without the adverse effects of antidepressant drugs.

“However, several remarks are important. First, the patients followed their preference, which is common practice, but ideally, we should advise patients what will work best.

“Following this choice is understandable from a pragmatic point of view when patients have strong preferences, which you have to take into account when doing a study like this.

“The downside is that the comparisons between groups might be biased compared to doing this in a truly randomized study.

“For example, patients in the antidepressant group were more depressed which might be associated with less chance of persisting engagement in the exercises.

“So, we have to be careful not to over-interpret the comparisons between groups, which the authors acknowledge properly.

“Finally, a very important finding is the difference in adherence between the interventions: 52 percent in the exercise group and 82 percent in the antidepressant group.

“This shows that it is more difficult to change a lifestyle habit than taking a pill. This is not exclusively found in psychiatry, indicating that we also have to focus on how to improve compliance to healthy behavior.

“This could have a tremendous impact on healthcare more generally, but also on psychiatric diseases.”

Produced in association with SWNS Talker